EyePoint, Inc.
Close on Oct 19, 2026
- Market cap
- $38.08K
- P/E (TTM)
- –
- Dividend yield
- –
About EyePoint
Laboratory Analytical Instruments, SIC 3826
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat serious retinal diseases. The company's pipeline utilizes its proprietary bioerodible Durasert E technology designed for sustained intraocular drug delivery. Its primary product candidate is DURAVYU, an investigational sustained-delivery therapy that pairs the tyrosine kinase inhibitor vorolanib with Durasert E to treat vascular endothelial growth factor-mediated retinal conditions, specifically wet age-related macular degeneration and diabetic macular edema. The company also advances EYP-2301 and maintains commercial arrangements regarding YUTIQ and DEXYCU for ophthalmic care.
The company operates manufacturing facilities located in Watertown, Massachusetts, and Northbridge, Massachusetts, and maintains collaboration and commercial supply agreements serving partner markets such as China. EyePoint maintains corporate headquarters in Watertown, Massachusetts.
Summary of the business section of EyePoint's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EyePoint, Inc.
- Headquarters
- Watertown, MA
- Address
- 480 Pleasant Street, Suite C400 02472
- Phone
- (617) 926-5000
- Website
- www.psivida.com
- Employees
- 214, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- EYPT
- Exchange
- Nasdaq
- IPO date
- Jan 27, 2005
- Shares outstanding
- 86M, Jul 31, 2026
- Public float
- $642.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Dec 9, 2020; 1-for-10 reverse, Dec 8, 2020; 1-for-4 reverse, Jun 11, 2008
- SEC CIK
- 1314102
- CUSIP
- 30233G209
- ISIN
- US30233G2093
- LEI
- 549300QE1RU34T50MR69
- EIN
- 26-2774444
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jay S. Duker | President and CEO, Director | 187,025 |
| George Elston | Chief Financial Officer | 122,470 |
| Ramiro Ribeiro | Chief Medical Officer | 4,875 |
| Karen L. Zaderej | Director | 49,100 |
| Nancy Lurker | Director | 421,235 |
| Reginald J. Sanders | Director | – |
| Wendy F. Dicicco | Director | 9,967 |
| John B. Landis | Director | 21,400 |
| Stuart Duty | Director | – |
| Goran Ando | Director | 13,150 |
| Fred Hassan | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $5.57M | $13.99M | $2.17M | $522 | – |
| FY2025 Jay Duker | $5.57M | $13.99M | $2.17M | $522 | – |
| FY2025 Nancy Lurker | $0 | $0 | $2.17M | $522 | – |
| FY2024 | $5.95M | -$3.64M | $3.35M | $213 | – |
| FY2024 Jay Duker | $5.95M | -$3.64M | $3.35M | $213 | – |
| FY2024 Nancy Lurker | $0 | $0 | $3.35M | $213 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 27, 2026, we had 214 employees, all of which were full-time, all located in the United States.”
Corporate history
Events identified from SEC filings